Investing.com -- Maze Therapeutics Inc (NASDAQ:MAZE) received bullish coverage from multiple analysts, with Guggenheim, JPMorgan, and TD Cowen initiating Buy or Overweight ratings on the company given its potential in genetically targeted therapies.
Maze's lead drug candidate, MZE829, is an oral APOL1 inhibitor being developed for APOL1-mediated kidney disease.
Analysts expect key Phase II HORIZON trial data in early 2026, with TD Cowen highlighting its potential to address over 1 million AKD patients and noting its potency advantage over Vertex's (NASDAQ:VRTX) inaxaplin.
Guggenheim sees Maze as a compelling investment, given the estimated $10 billion to $15 billion market opportunity in APOL1-associated kidney disease.
Beyond MZE829, Maze's pipeline includes MZE782, an SLC6A19 inhibitor targeting chronic kidney disease and phenylketonuria, with Phase I data expected in the second half of 2025. Analysts view it as a first-in-class therapy with significant commercial potential.
JPMorgan, which set a $30 price target, sees multiple catalysts for Maze, emphasizing the breadth of MZE829’s potential patient base and its differentiation from Vertex’s drug. Guggenheim set a $19 price target, citing value-inflecting data expected over the next year.
Related Articles
Maze Therapeutics receives positive ratings following recent IPO
Intuit earnings beat by $0.74, revenue topped estimates
Workday earnings beat by $0.14, revenue topped estimates
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。